Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.48 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720610 | 0.80 | NPFFR2 (0.53) | NPFFR2NPFFR1LMNATRPA1IDO1 | |
| SCHEMBL2908923 | 0.76 | NPFFR1 (0.49) | NPFFR2NPFFR1KDRHTR3EHTR3B | |
| SCHEMBL4800123 | 0.76 | NPFFR1 (0.49) | NPFFR2NPFFR1KDRHTR3EHTR3B | |
| SCHEMBL4800117 | 0.76 | NPFFR1 (0.49) | NPFFR2NPFFR1KDRHTR3EHTR3B | |
| SCHEMBL8997535 | 0.75 | NPFFR2 (0.45) | NPFFR2NPFFR1KDRHTR3EHTR3B | |
| SCHEMBL8997541 | 0.75 | NPFFR2 (0.45) | NPFFR2NPFFR1KDRHTR3EHTR3B | |
| SCHEMBL16952200 | 0.74 | NPFFR2 (0.57) | NPFFR2NPFFR1LMNAIDO1KDR | |
| SCHEMBL22787046 | 0.74 | NPFFR2 (0.39) | NPFFR2NPFFR1LMNATRPA1IDO1 | |
| SCHEMBL15298179 | 0.73 | ALDH1A1 (0.50) | NPFFR2NPFFR1LMNATRPA1KDR | |
| SCHEMBL3311082 | 0.73 | NPFFR1 (0.43) | NPFFR2NPFFR1LMNAKDRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024030529-A1 | PRODRUGS OF MYC INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20200390894-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF C-MYC PROTEIN | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390894-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF C-MYC PROTEIN | MYCBP, MYC, MYCBP2 | NPFFR2 4424/4885NPFFR1 4105/4885LMNA 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.